Abstract 1485P
Background
Pembrolizumab is the standard first-line treatment for patients with metastatic Non-Small Cell Lung Cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression of ≥50%. However, early loss of clinical benefit is observed in many cases. There is a need to identify predictors of this phenomenon in the real-world population.
Methods
This study is a retrospective analysis of patients (pts) with stage IV NSCLC treated with pembrolizumab in routine practice, who received treatment for at least 6 weeks. Inclusion criteria included good performance status (ECOG 0-1), no active brain metastases, and no EGFR or ALK alterations. The median progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The log-rank test and Cox regression model were used for uni- and multivariate analysis.
Results
A group of 216 pts were included. The objective response rate was 35.6%, 25.5% of pts had PD, while 11.2% of pts died before the first CT-scan. Median PFS and OS were 9.88 months (95% CI 4.85-14.92; 127 events) and 14.88 months (95% CI 9.84-19.91; 122 events), respectively. The median Systemic Inflammatory Index (SII) was 1260 in the overall population. In univariate analysis, SII >1260 had a negative impact on PFS (p=0.047) and OS (p<0.022). Tumour burden ≥111.5 mm (p<0.045) was a negative prognostic factor for OS. Other factors assessed were not relevant. An increase in the SII of more than 25% after 6 weeks of treatment correlated with a higher likelihood of early progression (p<0.001) and shorter OS (p<0.001). The differences were more pronounced in the subgroup of patients with an initial SII >1260. On multivariate analysis, higher tumour burden (HR 1.52, p=0.028, 95%CI 1.043-2.018) and an increase in SII at 6 weeks of more than 25% (HR 2.62, p<0.001;95%CI 1.625-4.234) were found to be negative prognostic factors for OS.
Conclusions
Pembrolizumab is effective in pts treated in daily practice. Taking into account additional factors, such as inflammatory index, may help to identify the optimal patient population. The dynamics of SII after 6 weeks of treatment may be a surrogate for clinical benefit.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Knetki-Wroblewska: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Roche, MSD, Takeda, Amgen, AstraZeneca, Boehringer Ingelheim, Ipsen; Financial Interests, Personal, Advisory Board: Takeda, Boehringer Ingelheim, Bristol Myers Squibb. A. Piórek: Financial Interests, Personal, Invited Speaker: MSD, BMS, AstraZeneca, Takeda. S. Tabor: Financial Interests, Personal, Invited Speaker: MSD, BMS; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Other, Travel grant: AstraZeneca. K. Winiarczyk: Financial Interests, Personal, Invited Speaker: BMS, Pfizer. P. Sobczuk: Financial Interests, Personal, Other, Travel grant: Novartis; Financial Interests, Personal, Other, Travel Grant: MSD, BMS; Financial Interests, Personal, Invited Speaker: Swixx BioPharma, BMS, Gilead; Financial Interests, Personal, Advisory Board: Sandoz; Financial Interests, Personal, Stocks/Shares: CelonPharma; Non-Financial Interests, Institutional, Product Samples: Immutep; Non-Financial Interests, Leadership Role, Board Member, Chair of Young Oncologists Section: Polish Society of Clinical Oncology. A. Pluzanski: Financial Interests, Personal, Invited Speaker: MSD, BMS, AstraZeneca, Roche, Pfizer; Financial Interests, Personal, Advisory Board: MSD, BMS. D.M. Kowalski: Financial Interests, Personal, Advisory Board: MSD, BMS; Financial Interests, Personal, Invited Speaker: MSD, BMS, AstraZeneca, Roche, Pfizer; Financial Interests, Personal and Institutional, Coordinating PI: MSD. M.J. Krzakowski: Financial Interests, Personal, Other, travel grant: MSD; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Other, Travel grant: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1523P - Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
Presenter: Mustapha Tehfe
Session: Poster session 21
1524P - First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C
Presenter: Lin Shen
Session: Poster session 21
1526P - Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1
Presenter: Zev Wainberg
Session: Poster session 21
1527P - Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification
Presenter: Jiajia Yuan
Session: Poster session 21
1528P - A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Presenter: Daniel Olson
Session: Poster session 21
1529P - Tislelizumab plus chemotherapy sequential neo-chemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT)
Presenter: Wenwu He
Session: Poster session 21
1530P - Health-related quality of life (hrqol) in patients with claudin-18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and GLOW
Presenter: Florian Lordick
Session: Poster session 21
1532P - Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy
Presenter: Shun Yamamoto
Session: Poster session 21